Clinical Trial Search

Primary: Number of Participants With Grades 1-4 Adverse Events That Are Possibly, Probably, and/or Definitely Attributed to Pomalidomide — 21; 10; 1; 0 Participants

Primary: Tumor Response Rate Every 4 Weeks — 4; 1 participants

Primary: Response Rate — 31 Percentage of participants

Primary: Preliminary Assessment of the Temperature of Kaposi's Sarcoma Lesions Compared to the Temperature in the Normal Skin Measured With Thermography — 1.1 Celsius

Primary: Number of Participants With Complete Response — 1; 3 participants

Primary: Kaposi Sarcoma (KS) Status at Week 48 Compared to Study Entry — 43; 47; 13; 9 Participants — p=0.911

Primary: Progression Free Survival — 186; 271 Days

Primary: Overall Survival (OS) — 21.5; 12.7; 26.6 months

Primary: Number of Participants Evaluated for Toxicity — 10 Participants

Primary: Minimal Response Rate in Pediatric Participants With Alveolar Soft Part Sarcoma (ASPS) — 0 Participants

Primary: Overall Response Rate — 0.577 proportion of participants

Primary: Total Score on Quality of Life Assessed Using Functional Assessment of Cancer Therapy-General (FACT-G) Questionnaire — 56.9 score on a scale

Primary: Number of Participants With a Decrease in Kaposi's Sarcoma (KS) Total Surface Area — 11 Participants

Primary: Objective Response Rate — 0; 7; 6 Participants

Primary: Efficacy of Therapeutic Escalation of Standard Dose Nelfinavir, Followed by High Dose Nelfinavir, for Treatment of Kaposi Sarcoma Lesions for HIV Positive Participants…